Systemic sclerosis is characterised by vascular endothelial damage. Platelets adhering to the exposed subendothelium may contribute to the inflammatory changes found in the vessel wail. Increased in vitro platelet aggregability in systemic sclerosis has been reported. In vitro platelet aggregation of platelet rich plasma obtained from patients with systemic sclerosis (CREST (calcinosis, Raynaud's phenomenon oesophageal dysmotility, sclerodactyly, telangiectasia) variant) and from controls matched for age and sex was compared. Collagen, ADP, and platelet activating factor were used as aggregating agents. The actions of a platelet activating factor antagonist, BN52063, were also examined.
Systemic sclerosis is characterised by vascular endothelial damage.' Endothelial damage in smaller arteries and arterioles leads to exposure of the subendothelium. Platelets adhering to the subendothelium may contribute to the inflammatory changes seen in the vessel wall by releasing inflammatory mediators. 2 In vitro studies have suggested that platelets from patients with systemic sclerosis are hyperactive.3 6If this is the case, thrombus formation at injured sites on vessel walls would be more extensive and platelets would be more likely to aggregate in the circulation on exposure to aggregating agents. Antiplatelet drugs may be clinically useful. Collagen is the basement membrane component responsible for platelet adherence, release, and aggregation. After adhesion to collagen the platelets release ADP. Platelet activating factor is a phospholipid considered to be an important inflammatory mediator, participating in many complex inflammatory and allergic disorders. It is a potent platelet aggregatory agent. We compared in vitro platelet aggregation in response to collagen, ADP, and platelet activating factor of platelet rich plasma obtained from patients with systemic sclerosis (CREST variant) and from controls matched for age and sex. The effects of BN50263, a specific platelet activating factor antagonist, on aggregation induced by platelet activating factor were also investigated.
Patients and methods

PATIENTS
Patients with systemic sclerosis (CREST variant) and normal controls matched for age and sex were selected for the study. Subjects more than 300/o overweight as defined by Health Education Council guidelines7 were excluded.
All subjects were asked to avoid a fatty breakfast and to refrain from smoking on the day of the study. Blood sampling took place at 9 00 am using a 19 gauge needle and with minimal tourniquet and trauma.
PREPARATION OF PLATELET RICH AND PLATELET POOR PLASMA
To prepare platelet rich plasma 20 ml blood was added to 3 ml acid-citrate-dextrose (34-7 mM citric acid, 74 
Results
PREPARATION OF PLATELET RICH PLASMA
Blood samples were taken from 12 female patients with systemic sclerosis and 12 female control subjects. Table 1 gives details of the patients.
Platelet rich plasma was prepared with mean platelet yields of 80-6 (SD 7 8)% in the patient group and 90'0 (10-2)% in the control group.
The mean platelet volume (table 2) was significantly lower in platelet rich plasma than 6 Normal platelet activation might have been seen because a subpopulation of hyperactive platelets had been consumed in vivo leaving only less reactive platelets in the circulation. The active platelets might have been 'exhausted' by being used in vivo during activation by exposed subendothelium at sites of endothelial damage. After aggregation and disaggregation the platelets would be returned to the circulation refractory to further stimulation by the same agonist. Alternatively, any hyperactive platelets might have been lost during preparation of the platelet rich plasma.
Comparison of the mean platelet volume and platelet distribution width in whole blood and platelet rich plasma supports this hypothesis as it was found that some of the larger, denser platelets were lost during centrifugation. Karpatkin and Charmatz reported that heavy, dense platelets are metabolically and functionally 8 more active.
Possibly, platelet hyperactivity occurs only at one particular stage of the disease process. The studies reported here were carried out mainly on patients with disease duration of more than five years. If platelet hyperactivity only occurs in patients with early disease, as reported by Friedhoff et al,4 it would not be seen in this patient group.
The results reported here provide no evidence in support of the hypothesis that platelet hyperactivity is a fundamental feature of systemic sclerosis. Disappointing results which have been obtained with antiplatelet drugs9 might have been because either platelet activation has less importance than has been previously suggested in systemic sclerosis or because complete inhibition of platelet activation has not yet been achieved. It has been shown that at concentrations of 1-100 imol/l BN52063 is a dose dependent, competitive antagonist of platelet aggregation induced in vitro by platelet activating factor, and it has no effect on ADP induced aggregation. BN52063 was the first platelet activating factor antagonist shown to be active in man.'0 Subsequent clinical trials have shown BN52063 to be effective in inflammatory disorders, including asthma"l 12 and systemic mastocytosis.13 Although normal platelet sensitivity to platelet activating factor was seen in systemic sclerosis, it is possible that platelet activation might be caused by hyperproduction of platelet activating factor occurring at some stage of the disease. If this is the case, a specific platelet activating factor antagonist may be beneficial in counteracting the effects of the large quantities of platelet activating factor produced. Platelet 
